(OPK) Opko Health - Overview
Stock: Diagnostics, Rayaldee, 4Kscore, hGH-CTP, SARM
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 44.7% |
| Relative Tail Risk | -11.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.59 |
| Alpha | -36.13 |
| Character TTM | |
|---|---|
| Beta | 0.784 |
| Beta Downside | 0.819 |
| Drawdowns 3y | |
|---|---|
| Max DD | 60.12% |
| CAGR/Max DD | 0.00 |
Description: OPK Opko Health January 19, 2026
OPKO Health (NASDAQ:OPK) operates two core segments: Diagnostics, anchored by BioReference Laboratories, which delivers a broad menu of clinical tests-including molecular diagnostics, genetics, and the 4Kscore prostate cancer assay-to physicians, hospitals, employers, and government entities; and Pharmaceuticals, which markets Rayaldee for secondary hyperparathyroidism and a pipeline of long-acting biologics (e.g., Somatrogon, Factor VIIa-CTP) and small-molecule programs such as OPK88004 (SARM) and OPK88003 (weekly peptide for type 2 diabetes/obesity). The company also leverages specialty API production and generic distribution across North America, Europe, and Latin America.
Key recent metrics: Q4 2023 revenue was $173 million, with the Diagnostics segment contributing roughly 58 % and growing at a 7 % YoY rate, while the Pharma segment’s pipeline generated $12 million in licensing and collaboration fees. The biotech sector’s valuation is being driven by an aging global population (projected 1.5 billion people over 65 by 2030) and expanding payer coverage for molecular diagnostics, which could lift OPKO’s test volume growth to double-digit rates if reimbursement trends hold. Additionally, the company’s long-acting growth-hormone (Somatrogon) has secured FDA approval in the EU, positioning it for a potential US launch pending Phase III data.
For a deeper quantitative assessment, you may find ValueRay’s OPK dashboard useful.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -140.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.11 > 0.02 and ΔFCF/TA -1.76 > 1.0 |
| NWC/Revenue: 71.30% < 20% (prev 58.75%; Δ 12.55% < -1%) |
| CFO/TA -0.10 > 3% & CFO -197.0m > Net Income -140.8m |
| Net Debt (-19.8m) to EBITDA (45.1m): -0.44 < 3 |
| Current Ratio: 3.70 > 1.5 & < 3 |
| Outstanding Shares: last quarter (779.9m) vs 12m ago 12.12% < -2% |
| Gross Margin: 38.62% > 18% (prev 0.25%; Δ 3837 % > 0.5%) |
| Asset Turnover: 30.20% > 50% (prev 31.53%; Δ -1.33% > 0%) |
| Interest Coverage Ratio: -0.43 > 6 (EBITDA TTM 45.1m / Interest Expense TTM 111.4m) |
Altman Z'' -5.80
| A: 0.23 (Total Current Assets 627.1m - Total Current Liabilities 169.3m) / Total Assets 2.00b |
| B: -1.13 (Retained Earnings -2.26b / Total Assets 2.00b) |
| C: -0.02 (EBIT TTM -48.2m / Avg Total Assets 2.13b) |
| D: -3.30 (Book Value of Equity -2.28b / Total Liabilities 690.0m) |
| Altman-Z'' Score: -5.80 = D |
Beneish M -3.42
| DSRI: 0.99 (Receivables 124.4m/138.7m, Revenue 642.1m/711.4m) |
| GMI: 0.65 (GM 38.62% / 25.10%) |
| AQI: 0.95 (AQ_t 0.63 / AQ_t-1 0.66) |
| SGI: 0.90 (Revenue 642.1m / 711.4m) |
| TATA: 0.03 (NI -140.8m - CFO -197.0m) / TA 2.00b) |
| Beneish M-Score: -3.42 (Cap -4..+1) = AA |
What is the price of OPK shares?
Over the past week, the price has changed by -1.59%, over one month by -6.06%, over three months by -10.14% and over the past year by -23.46%.
Is OPK a buy, sell or hold?
- StrongBuy: 2
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the OPK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 3.6 | 187.1% |
| Analysts Target Price | 3.6 | 187.1% |
| ValueRay Target Price | 1.2 | -2.4% |
OPK Fundamental Data Overview February 03, 2026
P/S = 1.5577
P/B = 0.741
P/EG = -2.87
Revenue TTM = 642.1m USD
EBIT TTM = -48.2m USD
EBITDA TTM = 45.1m USD
Long Term Debt = 331.4m USD (from longTermDebt, last quarter)
Short Term Debt = 24.3m USD (from shortTermDebt, last quarter)
Debt = 395.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -19.8m USD (from netDebt column, last quarter)
Enterprise Value = 980.4m USD (1.00b + Debt 395.4m - CCE 415.2m)
Interest Coverage Ratio = -0.43 (Ebit TTM -48.2m / Interest Expense TTM 111.4m)
EV/FCF = -4.62x (Enterprise Value 980.4m / FCF TTM -212.1m)
FCF Yield = -21.63% (FCF TTM -212.1m / Enterprise Value 980.4m)
FCF Margin = -33.03% (FCF TTM -212.1m / Revenue TTM 642.1m)
Net Margin = -21.93% (Net Income TTM -140.8m / Revenue TTM 642.1m)
Gross Margin = 38.62% ((Revenue TTM 642.1m - Cost of Revenue TTM 394.1m) / Revenue TTM)
Gross Margin QoQ = 46.99% (prev 31.50%)
Tobins Q-Ratio = 0.49 (Enterprise Value 980.4m / Total Assets 2.00b)
Interest Expense / Debt = 2.87% (Interest Expense 11.4m / Debt 395.4m)
Taxrate = 47.78% (19.8m / 41.4m)
NOPAT = -25.2m (EBIT -48.2m * (1 - 47.78%)) [loss with tax shield]
Current Ratio = 3.70 (Total Current Assets 627.1m / Total Current Liabilities 169.3m)
Debt / Equity = 0.30 (Debt 395.4m / totalStockholderEquity, last quarter 1.31b)
Debt / EBITDA = -0.44 (Net Debt -19.8m / EBITDA 45.1m)
Debt / FCF = 0.09 (negative FCF - burning cash) (Net Debt -19.8m / FCF TTM -212.1m)
Total Stockholder Equity = 1.32b (last 4 quarters mean from totalStockholderEquity)
RoA = -6.62% (Net Income -140.8m / Total Assets 2.00b)
RoE = -10.67% (Net Income TTM -140.8m / Total Stockholder Equity 1.32b)
RoCE = -2.92% (EBIT -48.2m / Capital Employed (Equity 1.32b + L.T.Debt 331.4m))
RoIC = -1.47% (negative operating profit) (NOPAT -25.2m / Invested Capital 1.71b)
WACC = 6.73% (E(1.00b)/V(1.40b) * Re(8.80%) + D(395.4m)/V(1.40b) * Rd(2.87%) * (1-Tc(0.48)))
Discount Rate = 8.80% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.87%
Fair Price DCF = unknown (Cash Flow -212.1m)
EPS Correlation: 35.49 | EPS CAGR: 14.75% | SUE: 1.03 | # QB: 2
Revenue Correlation: -82.71 | Revenue CAGR: -22.86% | SUE: -1.05 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.08 | Chg30d=+0.010 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.31 | Chg30d=+0.040 | Revisions Net=-1 | Growth EPS=+5.4% | Growth Revenue=-2.9%